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Purpose: Sensitive detection of cancer foci in men experiencing biochemical
recurrence following initial treatment of prostate cancer is of great clinical sig-
nificance with a possible impact on subsequent treatment choice. We describe a
multisite experience of the efficacyand safety of thepositron emission tomography/
computerized tomography agent fluciclovine (18F) after biochemical recurrence.
Materials and Methods: A total of 596 patients underwent fluciclovine (18F)
positron emission tomography/computerized tomography at 4 clinical sites.
Detection rate determinations were stratified by the baseline prostate specific
antigen value. Diagnostic performance was assessed against a histological
reference standard in 143 scans.
Results: The subject level fluciclovine (18F) positron emission tomography/
computer tomography detection rate was 67.7% (403 of 595 scans). Positive
findings were detected in the prostate/bed and pelvic lymph node regions in
38.7% (232 of 599) and 32.6% of scans (194 of 596), respectively. Metastatic
involvement outside the pelvis was detected in 26.2% of scans (155 of 591). The
subject level detection rate in patients in the lowest quartile for baseline prostate
specific antigen (0.79 ng/ml or less) was 41.4% (53 of 128). Of these patients 13
had involvement in the prostate/bed only, 16 had pelvic lymph node involvement
without distant disease and 24 had distant metastases. The positive predictive
value of fluciclovine (18F) positron emission tomography/computerized tomogra-
phy scanning for all sampled lesions was 62.2%, and it was 92.3% and 71.8% for
extraprostatic and prostate/bed involvement, respectively. Fluciclovine (18F) was
well tolerated and the safety profile was not altered following repeat
administration.
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Abbreviations
and Acronyms
ADT ¼ androgen deprivation
therapy
BCR ¼ biochemical recurrence
BED-001 ¼ Retrospective
Observational Study Investigating
Fluciclovine (18F) (FACBC)
CT ¼ computerized tomography
DR ¼ detection rate
FACBC ¼ fluciclovine (18F)
MRI ¼ magnetic resonance
imaging
PET ¼ positron emission
tomography
PPV ¼ positive predictive value
PSA ¼ prostate specific antigen
PSMA ¼ prostate specific
membrane antigen
SOT ¼ standard of truth
TRUS ¼ transrectal ultrasound
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Conclusions: Fluciclovine (18F) is well tolerated and able to detect local and distant prostate cancer recur-
rence across a wide range of prostate specific antigen values.
Key Words: prostatic neoplasms; neoplasm recurrence, local; positron-emission tomography;
flucovine F-18; tomography, emission-computed
PROSTATE cancer is the second most frequent cause of
cancer related death for men in the United States.1
Following initial diagnosis the majority of men
receive treatment, usually by prostatectomy or
radiation/brachytherapy.2 Recurrence, based on
rising levels of PSA, occurs in 20% to 50% of
cases.3e5 Furthermore, approximately 25% of men
experiencing BCR progress to metastatic disease
associated with significantly increased morbidity
and mortality rates.6,7 Consequently, BCR repre-
sents a critical juncture in disease progression and
is potentially the last opportunity for curative
therapy in many men.
Focal salvage therapies have demonstrated long-
term biochemical control rates of 30% to 70%,8,9
although careful selection of patients most likely
to benefit is warranted due to their inherent toxicity
and morbidity potential.8e10 Patients receiving
focal therapy in the presence of radiographically
occult metastatic disease experience inevitable
relapse and many patients elect observation until
metastatic disease is confirmed or they elect treat-
ment with ADT. The use of observation or ADT (the
latter is associated with side effects, including
sexual dysfunction, osteoporosis and metabolic dis-
ease11,12) in patients who could potentially be
treated with curative intent is of equal concern as
the delivery of focal therapy in patients with occult
metastases.
When considering focal therapies, the accurate
identification of disease stage and location is critical
to ensure appropriate selection of patients without
systemic involvement and guide treatment to spe-
cific involved regions. While PSA level and kinetics
(PSA doubling time) provide information on risk of
metastatic involvement, standard of care imaging,
generally pelvic CT or MRI and bone scintigraphy,
has a low diagnostic yield of only 11% of patients for
visualizing sites of disease.13 Thus, there is a clear
need for better imaging approaches.
Encouraging reports of the diagnostic perfor-
mance of the synthetic amino acid PET tracer
FACBC, that is fluciclovine (18F), in patients with
BCR in 2 single center studies have been published
previously.14e16 The aim of the current study was to
pool efficacy and safety data on patients with BCR
who had received at least 1 injection of fluciclovine
(18F) to generate a multicenter data set supporting
an evaluation of key determinants of diagnostic
performance in relation to the incident PSA level at
the time of patient scanning. Fluciclovine (18F) was
recently approved by the FDA (Food and Drug
Administration) for use in this indication.
MATERIALS AND METHODS
Patient Selection
This study, BED-001 (ClinicalTrials.gov NCT02443571),
was performed as a retrospective analysis of fluciclovine
(18F) in patients who had received at least 1 injection for
the detection of suspected BCR after primary surgery or
radiotherapy. The protocol was reviewed according to
local regulations and patient informed consent obtained
as required.
Patient data from November 28, 2007 to August 28,
2014 were pooled from a compassionate use program/
registry in Norway and from 2 published clinical studies
done at Emory University14 and Bologna Hospital,16
respectively. Patients in the Emory University study
were enrolled on the basis of a negative bone scan.14 The
majority of patients enrolled in the Bologna study
underwent no conventional imaging for suspected BCR,16
in accordance with EAU (European Urology Association)
guidelines. Patients were included in the Norwegian
fluciclovine registry at the discretion of the referring
physician.
A subpopulation of patients had sufficient data avail-
able to calculate diagnostic performance vs histology.
They comprised the population for the primary SOT
analyses.
Fluciclovine (18F) Positron Emission
Tomography/Computerized Tomography
Imaging Protocols. Fluciclovine (18F) was manufactured
by automated radio synthesis. At each clinical site
the type of PET/CT scanner and specific imaging
acquisition protocol were selected. The mean injected
activity (or dose) was 310 MBq (median 309, range 140
to 485).
Scan Interpretation. Fluciclovine (18F) PET/CT scan im-
ages were evaluated by experienced PET/CT readers prior
to data collection. Specific anatomical locations (lesions)
were classified as positive, negative or indeterminate
for malignancy based on visual assessment of non-
physiological activity against an appropriate background
in a manner analogous to clinical FDG (fluorodeox-
yglucose) reading.17 The imaging positivity rate or DR,
defined as the proportion of scans containing 1 or more
areas considered positive for cancer, was derived at the
subject and region levels. Regions of interest included
the prostate/bed (residual prostate, prostate bed and
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seminal vesicles), the pelvic lymph nodes, skeletal
metastases, other metastatic locations (excluding pelvic
lymph nodes) and extraprostatic sites (any lymph node,
bone or soft tissue metastasis).
Histological Reference Standards
The reference standard for the available primary SOT
cohort was histological confirmation. For the prostate/bed
region standard TRUS/biopsy or MRI/TRUS fusion biopsy
were used to establish truth while blinded to PET find-
ings. When feasible, clinically relevant fluciclovine (18F)
positive extraprostatic areas underwent directed biopsy
based on cognitive fusion of the PET/CT data with biopsy
technique. Because histological sampling of fluciclovine
(18F) negative extraprostatic sites was not feasible, all
diagnostic performance measures were not calculable for
this region.
Analyses
Statistical. The safety analysis set comprised all patients
with data included in the BED-001 database. The
effectiveness analysis set, which comprised all patients in
the database with fluciclovine (18F) scan data available,
was used to calculate the fluciclovine (18F) DR. To assess
effectiveness end points indeterminate lesions were
excluded from lesion and subject level analyses. At the
region level indeterminate lesions were excluded only for
the region involved and, thus, denominators varied.
Sensitivity analyses allocating indeterminate lesions as
positive or negative were performed.
Fluciclovine (18F) DR at the region and subject levels
was compared to quartiles of PSA at the time of scanning
for the total cohort and for each clinical site. The point
estimate and the 2-sided 95% exact CI were calculated
using the method of Clopper and Pearson.18
For the primary SOT cohort the primary effectiveness
end point was the lesion level PPV of fluciclovine (18F)
PET/CT. The point estimate and the 2-sided 95% exact
CI were calculated. The 1-sided exact binomial test was
used to compare H0 (end point 0.50) vs H1 (end point
0.50 or greater). Region level sensitivity, specificity, PPV
and negative predictive value were calculated, where
feasible.
Safety. The occurrence of adverse events until 35 days
after administration experienced by patients who received
fluciclovine (18F) was determined from site records.
RESULTS
Demographics
A total of 596 patients with BCR received 651 fluci-
clovine (18F) administration. Of the 628 fluciclovine
(18F) scans collected 33 revealed 1 or more lesions
classified as indeterminate. A total of 143 patient
scans, excluding 4 indeterminate scans, from 136
patients could be correlated with histology (table 1 ½T1).
Table 2 ½T2lists demographics and select baseline
characteristics for the effectiveness analysis set and
primary standard of truth populations, when
available. Demographics were similar between the
overall and primary SOT populations except a
higher proportion of patients in the primary SOT
population had disease recurrence after radio-
therapy. At the time of scanning 15 patients (2.5%)
were receiving ADT.
Detection Rate Analysis
At the subject level the fluciclovine (18F) PET/CT
DR was 67.7% (403 of 595). At the region level the
DR was 38.7% (232 of 599) in the prostate/bed and
32.6% (194 of 596) in the pelvic lymph nodes. Met-
astatic involvement outside the pelvis was detected
in 26.2% of patient scans (155 of 591), including
skeletal sites in 9% (55 of 610) of cases. Findings in
nonnodal soft tissue were uncommon at less than
1% of cases. On bone/CT scan 19 patients had pos-
itive findings within 3 months before and 6 months
after fluciclovine scanning. Figure 1 ½F1shows repre-
sentative fluciclovine (18F) PET/CT positive cases.
The impact of the PSA value at the time of
scanning on fluciclovine (18F) PET/CT DR was
investigated (fig. 2 ½F2). Overall, the subject level DR
was 41.4% (53 of 128 patients) in the lowest quartile
of PSA (0.79 ng/ml or less). Of 53 these patients 13
had involvement in the prostate/bed only, 16 had
pelvic lymph node involvement without more
distant disease and 24 had distant metastases.
Figure 3 ½F3shows a case in which fluciclovine (18F)
PET/CT detected lymph node involvement proximal
to the rectal wall, a location that renders the
Table 1. Clinical site contribution to effectiveness analysis set and primary standard of truth populations
Site Pt Cohort Source
No. Subjects with Fluciclovine (18F) Scan*/
No. Subject Images Analyzed
No. Effectiveness
Analysis Set
Primary Standard
of Truth
Overall e 596/595 136/143
Emory University, Atlanta, GA Clinical study: 18F-FACBC PET-CT for the Detection and
Staging of Recurrent Prostate Carcinoma (CA129356-01)
137/127 98/105
Ospedale Sant’Orsola, Bologna, Italy Clinical study: Anti-3-18F-FACBC vs 11C-choline PET/CT in
evaluating patients with suspected prostate cancer recurrence
88/90 12/12
Oslo University Hospital, Oslo, Norway Compassionate use experience/registry study 225/146 26/26
Aleris Helse AS, Oslo, Norway Compassionate use experience 146/255 0/0
Excluding all intermediate results.
*Underwent fluciclovine (18F) scan or scan is available.
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delivery of salvage radiotherapy problematic. The
patient went on to receive hormonal therapy.
Diagnostic Performance Determined vs Primary
Standard of Truth
Of the 143 patients included in the primary SOT
analysis 119 (83.2%) had a positive fluciclovine (18F)
PET/CT scan. A total of 553 lesion locations were
verified histologically. Table 3½T3 lists diagnostic per-
formance measures.
At the region level the PPV for extraprostatic
involvement was 92.3% (36 of 39 cases, 95% CI
79e98) and for prostate/bed disease it was 71.8% (74
of 103, 95%CI62e80). Lesion level analysis involving
all prostatic and extraprostatic lesionswith histology
resulted in a combined PPV of 62.2% (153 of 246
cases, 95% CI 55.8e68.3), which exceeded the pre-
determined null hypothesis. Sensitivity analysis had
no statistically significant bearing on the results.
Safety Analysis
The safety analysis set comprised 596 patients who
received a total of 651 fluciclovine (18F) adminis-
trations. Many patients had medical conditions
typical of an aging population, including cardio-
vascular disease and diabetes, and they were
receiving concomitant medications.
Treatment emergent adverse events were experi-
enced by 5.4% of patients (32 of 596). None were
considered adverse reactions to fluciclovine (18F),
including 2 (hypertension and abdominal bleeding)
that were considered serious. Eight reported nonse-
rious events (1.3%) were incidental synchronous
cancer findings, including 2 cases (0.3%) each of
breast cancer and lung neoplasm, and 1 (0.2%) each
of adenocarcinoma of the colon, gastrointestinal
stromal tumor; nonHodgkin lymphoma and rectal
cancer. Nine patients were noted to have extravasa-
tion of the injection with no clinical sequelae.
Laboratory reports of increased creatinine and
decreased hemoglobin were considered possibly
related by the investigator. However, interpretation
was confounded by preexisting diabetes and hyper-
tension, and bone metastases, respectively, suggest-
ing no causal association. The safety profile was not
noticeably altered following repeat administration.
DISCUSSION
Due to the poor performance of current imaging,
several radiopharmaceuticals have been evaluated for
BCR but they have proved limited in performance
and/or accessibility. PSMA targeted 111In capromab-
pendetide demonstrates suboptimal diagnostic
performance,19 (18F) FDG PET/CT provides low
sensitivity,20 (18F)-fluoride PET is limited to the
detection of bone metastases, country specific regula-
tory approval restricts 18F-choline PET/CT use in
Europe and the short half-life of 11C-choline confines
Table 2. BED-001 study patient demographics and select baseline characteristics
Recurrent Prostate Ca Primary Standard of Truth
No. subjects 596 140
No. scans:
Excluding indeterminate 595 143
Including indeterminate 628 147
Mean/median age (range) 67/67 (42e90) 67/68 (47e90)
No. race/nationality (%): 585 (98.2) 133 (95)
Black/African American 26 (4.4) 16 (11.4)
South Asian 1 (0.17) 1 (0.7)
White 186 (31.2) 88 (62.9)
Other 1 (0.17) 0
Missing 11 (1.85) 7 (5)
Norwegian (predominantly white) 371 (62.3) 28 (20)
Baseline PSA:*
No. pts (%) 537 (90.1) 132 (94.3)
Mean ng/ml/median (range) 5.43/2.0 (0.05e82.0) 6.26/3.635 (0.11e44.76)
No. initial therapy (%): 575 (96.5) 140 (100)
Prostatectomy only 130 (21.8) 7 (5)
Prostatectomy þ other (not radiotherapy) 62 (10.4) 11 (7.9)
Radiotherapy only 76 (12.8) 4 (2.9)
Radiotherapy þ other (including radical prostatectomy) 266 (44.6) 92 (65.7)
Other† 41 (6.9) 26 (18.6)
Gleason score:
No. pts (%) 355 (60) 110 (79)
Mean 7.4 6.7
No. D’Amico class (%): 596 (100) 140 (100)
Low risk 8 (1) 5 (4)
Intermediate risk 108 (18) 45 (32)
High risk 277 (47) 43 (31)
Indeterminate 203 (34) 47 (34)
*Baseline defined as last value prior to first fluciclovine (18F) administration.
†Neither radical prostatectomy nor radiotherapy.
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its use in the United States to centers with a cyclotron
on site. Second generation PSMA targeting agents
showpromisebutarestill early in formaldevelopment.
In this study we explored the safety and efficacy
of fluciclovine (18F) in BCR. Importantly for a
diagnostic product, the agent appeared well toler-
ated. Although any radiopharmaceutical agent ex-
poses patients to additional radiation with the
possible long-term risk of secondary cancers, the
benefit-to-risk ratio appears favorable in a mainly
elderly population experiencing disease recurrence.
Fluciclovine (18F) PET/CT visualizes local recur-
rence and extraprostatic metastases with a corre-
lation between DR and PSA levels, as observed for
other agents.21 Of particular importance is the
detection of extraprostatic involvement in approxi-
mately 30% of patients in the PSA quartile 0.79 ng/
ml or less, most likely representing patients with
post-prostatectomy recurrence. In the cohort with
histological confirmation the PPV for detecting
extraprostatic disease was greater than 90%.
Figure 3. In 61-year-old male with PSA rising to 0.4 ng/ml after
robot-assisted laparoscopic prostatectomy fluciclovine
transverse PET/CT detected 8 mm mesorectal lymph node
metastasis (arrow).
Figure 2. Impact of PSA on fluciclovine (18F) PET/CT detection
rate at subject and region levels in combined data set.
Figure 1. A, in 68-year-old male after radical EQ2prostatectomy with PSA rising to 0.4 ng/ml fluciclovine (18F) transverse PET/CT detected
recurrence (arrow) in left prostate bed. B, in 67-year-old male after radical prostatectomy with sipuleucel-T and bicalutamide, PSA
rising to 0.91 ng/ml and negative bone scan sagittal fluciclovine (18F) PET/CT detected 3 to 4 mm presacral node (arrow). C, in
64-year-old male after radical prostatectomy with PSA rising rapidly to 3.7 ng/ml 2 weeks before scanning transverse fluciclovine
(18F) PET/CT (bone window) detected solitary bone metastasis (arrow) in right proximal femur.
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Sensitivity for detecting local recurrence
approached 90%, although the 72% PPV and 33%
specificity were suboptimal. This was possibly due
to an overlap of malignancy with benign hyperpla-
sia and prostatitis, as in primary disease,22,23 and/or
to the sampling error of conventional TRUS biopsy
as the SOT.24 We believe that the histological SOT
used in this study represents a conservative
approach to the estimation of fluciclovine (18F) per-
formance. Utilizing TRUS/PET fusion biopsy as the
SOT will likely prove valuable, as will exploration of
specificity optimization imaging techniques.25
Reports in the literature relating to the perfor-
mance of choline PET agents are highly variable,
mainly due to differences in the tracer and PET
equipment/protocols used, and the divergent ap-
proaches to truth determination.21 The Bologna
cohort included in BED-001 contributed to a pro-
spective intrapatient comparison of fluciclovine
(18F) to 11C-choline demonstrating a statistically
significant superior sensitivity for fluciclovine (18F)
at baseline PSA less than 1 ng/ml.15
A comparison of the performance of fluciclovine
(18F) and PSMA-PET agents is hindered by reports of
variable performance from single center experiences.
For 68Ga-PSMA-HBED-CC DRs of 48% (PSA less
than 0.83 ng/ml) and 58% (PSA 0.2 to less than 0.5
ng/ml) have been published.26,27 Prospective study is
needed to establish the relative performance of flu-
ciclovine (18F) compared to various PSMA agents.
Our series presents an extensive multicenter
experience of fluciclovine (18F) in BCR. However, it
was subject to several limitations, including the lack
of prospective inclusion of all patients, variable use
of comparative imaging, the lack of histological
verification and standardized biopsy technique, and
the lack of systematic capture of information on a
change in patient treatment. Notwithstanding these
limitations, it is clear that fluciclovine (18F) may
have a significant impact on the selection of patients
for focal therapy and for the guidance of such
therapy to involved areas. Indeed, Scriebmann et al
recently reported preliminary findings in a cohort of
41 patients scheduled for salvage radiotherapy
(median PSA 0.43 ng/ml), in whom 46 fluciclovine
(18F) lesions (83.6%) were borderline or outside the
standard planning volumes, leading to the
augmentation of standard target volumes.28
Due to national differences in imaging guidelines,
it is not feasible to give universal recommendations
for fluciclovine (18F) use in clinical practice in rela-
tion to other techniques. Nevertheless, it is clear
that fluciclovine (18F) could be considered in cases in
which conventional imaging with bone scan and
standard CT/MRI are negative. Furthermore, the
accurate assessment of lymph node involvement by
standard CT/MRI based on differential size/shape
determinants is hindered by the dual problems of
low sensitivity and specificity. Therefore, this pre-
sents an opportunity for replacement with fluciclo-
vine (18F) PET/CT. At this time we recommend
continuing dedicated bone imaging alongside fluci-
clovine (18F) until further evidence is generated in
high risk populations.
Future study should confirm utility in terms of
progression and survival measures after fluciclovine
(18F) guided salvage. Further understanding of flu-
ciclovine (18F) performance in populations stratified
by prior treatment, PSA doubling time, Gleason
score, PET equipment and acquisition variations
will prove valuable and should help inform patient
selection for scanning.
CONCLUSIONS
Fluciclovine (18F) is well tolerated and able to detect
local and distant prostate cancer recurrence across
a wide range of PSA values. Work is under way to
strengthen the evidence base of the demonstrable
management impact on BCR and explore applica-
tion in additional aspects of prostate cancer care
and in other cancers.
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Table 3. Fluciclovine (18F) PET-CT outcomes vs primary standard of truth at lesion, region and subject levels in patients with recurrent
prostate cancer
Lesion
Region
SubjectProstate/Bed Extraprostatic
No. pts (%): 553 127 44 143
Pos 153 (27.7) 74 (58.3) 36 (81.8) 98 (68.5)
False-pos 93 (16.8) 20 (22.8) 3 (6.8) 21 (14.7)
Neg 216 (39.1) 14 (11.0) 1 (2.3) 14 (9.8)
False-neg 91 (16.5) 10 (7.9) 4 (9.1) 10 (7.0)
No./total No. (%)/(95% CI)
Pos predictive value 153/246 (62.2)/(56, 68) 74/103 (71.8)/(62, 80) 36/39 (92.3)/(79, 98) 98/119 (82.4)/(74, 89)
Neg predictive value 216/307 (70.4)/(65, 75) 14/24 (58.3)/(37, 78) Not applicable 14/24 (58.3)/(37, 78)
Sensitivity 153/244 (62.7)/(56, 69) 74/84 (88.1)/(79, 94) Not applicable 98/108 (90.7)/(84, 96)
Specificity 216/309 (69.9)/(65, 75) 14/43 (32.6)/(19, 49) Not applicable 14/35 (40.0)/(24, 58)
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EDITORIAL COMMENTS
Today choline-PET/CT is the most widespread imag-
ing technique for assessing PCa relapse. It can detect
the site of recurrence with lower PSA compared to
conventional imaging. Preliminary clinical reports of
18F-FACBC showed an improvement in the detection
rate of 20% to 40% in comparison to 11C-choline.1
Further studies comparing these 2 radiotracers
demonstrated similar results (reference 15 in article).
Nevertheless, 18F-FACBC has some peculiar advan-
tages, such as a shorter synthesis time as well as a
longer half-life of 109 minutes. This allows for PET
imaging without a cyclotron on site, thus, improving
the availability of this technique.
When we look to possible salvage therapy for
patients with biochemical relapse after radical
treatment, both choline and 18F-FACBC still have a
suboptimal detection rate since it is strongly related
to PSA levels. To address this void, the new PET
tracer 68Ga-PSMA revealed incredibly higher detec-
tion rate evenwith PSA less than 0.5 ng/ml compared
with choline.2 It had superior diagnostic performance
in metastatic PCa assessment and some potential
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therapeutic consequences. Nevertheless, nowadays
some suspicions have arisen regarding a possible
high rate of false-positive results of 68Ga-PSMA.
Thus, the competition is open and future compara-
tive studies will show us the winner.
Riccardo Schiavina
Department of Urology
S. Orsola-Malpighi Hospital
University of Bologna
Bologna, Italy
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The authors describe a multicenter experience of
the efficacy and safety of the PET/CT agent
fluciclovine (18F) following BCR in 596 patients. On
a patient basis the overall detection rate was 67.7%
(403 of 595) whereas the detection rate in patients
in the lowest quartile of baseline PSA (less than
0.79 ng/ml) was 41.4% (53 of 128). Additionally,
injections were well tolerated in the entire study.
Currently, further evaluation of patients with
BCR using novel PET tracers is an emerging
research topic. PSMA targeting agents and
18F-choline are among the most popularly studied
tracers. Despite reported promising results with a
number of tracers, the greatest limitation is vali-
dation with histopathology. In the current paper the
authors correlated imaging findings in 136 patients,
which is quite important and promising to docu-
ment the impact of fluciclovine (18F) in those with
BCR. Further research with different tracers with
histopathology validation is needed to better docu-
ment tumor foci in BCR.
Baris Turkbey
National Cancer Institute
National Institutes of Health
Bethesda, Maryland
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